Navigation Links
Interim Results Presented at EASL from PROVE 1 Clinical Trial of,Investigational Drug Telaprevir in Patients with Genotype 1,Hepatitis C

BARCELONA, Spain--(BUSINESS WIRE)--Apr 14, 2007 - In a late-breaker presentation at the 42nd Annual Meeting of the European Association for the Study of the Liver (EASL), researchers today presented data from a planned interim analysis of the PROVE 1 clinical trial, which is the first trial to evaluate short-duration therapy with the investigational hepatitis C protease inhibitor telaprevir (TVR, VX-950) in combination with pegylated interferon (peg-IFN) and ribavirin (RBV) in treatment-naive, genotype 1-infected hepatitis C patients. The data from PROVE 1 demonstrated a high rate of rapid viral response (RVR) in the telaprevir groups and a low rate of on-treatment viral breakthrough, and suggested that 12 weeks of telaprevir-based therapy enabled some patients to clear the virus. Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) is developing telaprevir in collaboration with Tibotec.

"The high rates of RVR observed in the telaprevir groups in PROVE 1, and the fact that some patients have remained persistently viral negative 20 weeks after stopping the 12 weeks of telaprevir-based therapy, suggest that we may be able to shorten the treatment duration in genotype 1 HCV patients," said John McHutchison, M.D., Principal Investigator for the PROVE 1 study and Director of Gastroenterology and Hepatology Research at Duke Clinical Research Institute. "These interim results are encouraging and suggest that high sustained viral response (SVR) rates may be achieved with regimens that are 24 weeks in total duration. We look forward to 24 week follow-up data from the initial group of patients who stopped treatment at 12 weeks, and follow-up data from patients in the study who received 24 weeks of treatment."

PROVE 1 Summary

-- 88% and 79% of patients receiving telaprevir achieved a rapid viral response (RVR) as measured by plasma HCV RNA (less than)30 IU/mL and (less than)10 IU/mL, respectively, at 4 weeks.<
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
3. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
4. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
5. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
6. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
7. Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer
8. Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal
9. Avalon Pharmaceuticals Announces Positive Interim Results For AVN944 Phase I Trial
10. Vical Interim Clinical Results Demonstrate Safety and Tolerability of Inovio Biomedicals Electroporation DNA Delivery Technology
11. Interim Data From RECORD Study Show No Significant Difference Between Avandia and Standard Therapy in Risk of Cardiovascular Hospitalization or Death
Post Your Comments:
(Date:7/31/2014)... Therapeutics, Inc. (NASDAQ: SRNE ; Sorrento) today announced ... Officer and Executive Vice President. Mr. Singh died suddenly and ... "Sorrento is deeply saddened and shocked by the loss of ... Amar,s family and friends," said Henry Ji , Ph.D., ... Singh joined Sorrento in January 2014 from Synta Pharmaceuticals, where ...
(Date:7/31/2014)... 2014 IRIDEX Corporation (Nasdaq: IRIX ) ... months ended June 28, 2014.  , Revenues were ... from $9.2 million in the 2013 second quarter and up ... Revenues for the first six months of 2014 were $20.9 ... months of last year. , Gross margin for the ...
(Date:7/31/2014)... Tandem Diabetes Care®, Inc. (NASDAQ: TNDM ... Insulin Pump, today reported its financial results for the quarter ... second quarter of 2014 to the same period of 2013: ... $5.5 million , t:slim Pump shipments grew 64 percent ... six months ended June 30, 2014 to the same period ...
Breaking Medicine Technology:Sorrento Announces the Unexpected Death of its Chief Business Officer 2IRIDEX Reports 2014 Second Quarter, Six-Month Results 2IRIDEX Reports 2014 Second Quarter, Six-Month Results 3IRIDEX Reports 2014 Second Quarter, Six-Month Results 4IRIDEX Reports 2014 Second Quarter, Six-Month Results 5IRIDEX Reports 2014 Second Quarter, Six-Month Results 6IRIDEX Reports 2014 Second Quarter, Six-Month Results 7Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 2Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 3Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 4Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 5Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 6
... WASHINGTON, Sept. 15 A home medical equipment provider ... "competitive" bidding program for durable medical equipment and services. ... and wound care specialist at Allcare Medical, in Sayreville, ... on Health that the bidding program, as designed by ...
... Angioslide Commercializes in the U.S. First Device to Combine Balloon Angioplasty and... -- MINNEAPOLIS, Minnesota, September 15, ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... BitlyCB.alertResponse = function(data) { var s = ,; var first_result; // Results are keyed by longUrl, so ...
Cached Medicine Technology:Homecare Provider Testifies on Downside of Medicare 'Competitive' Bidding Program Before House Energy and Commerce Subcommittee 2Homecare Provider Testifies on Downside of Medicare 'Competitive' Bidding Program Before House Energy and Commerce Subcommittee 3Homecare Provider Testifies on Downside of Medicare 'Competitive' Bidding Program Before House Energy and Commerce Subcommittee 4Homecare Provider Testifies on Downside of Medicare 'Competitive' Bidding Program Before House Energy and Commerce Subcommittee 5Homecare Provider Testifies on Downside of Medicare 'Competitive' Bidding Program Before House Energy and Commerce Subcommittee 6Homecare Provider Testifies on Downside of Medicare 'Competitive' Bidding Program Before House Energy and Commerce Subcommittee 7Angioslide Commercializes in the U.S. First Device to Combine Balloon Angioplasty and Embolic Capture 2Angioslide Commercializes in the U.S. First Device to Combine Balloon Angioplasty and Embolic Capture 3Angioslide Commercializes in the U.S. First Device to Combine Balloon Angioplasty and Embolic Capture 4Angioslide Commercializes in the U.S. First Device to Combine Balloon Angioplasty and Embolic Capture 5Angioslide Commercializes in the U.S. First Device to Combine Balloon Angioplasty and Embolic Capture 6Angioslide Commercializes in the U.S. First Device to Combine Balloon Angioplasty and Embolic Capture 7Angioslide Commercializes in the U.S. First Device to Combine Balloon Angioplasty and Embolic Capture 8
(Date:8/1/2014)... August 01, 2014 A new study ... that carbohydrates may contribute to the development of colorectal ... the disease. The study was authored by Alberto Martin ... found to cause intestinal cells to multiply and create ... colorectal cancer. , “What’s interesting about this study,” ...
(Date:8/1/2014)... August 01, 2014 This week marks ... completes its 500th week of paying commissions to its ... was founded in January 2005 total $1,405,954,677.06. , MonaVie ... world. The company pays commissions in 18 different currencies, ... MYR, MXN, NZD, PLN, USD, SGD, KRW, TWD, THB ...
(Date:8/1/2014)... A leading dress supplier, Discount-Dress.com, explores a variety of ... any lady’s wardrobe fashionable and exciting. Recently, the company has ... To attract more people, it is now launching a special ... to 65% off. , “Summer is the season of short ... to our collection of ‘ 2014 summer short styles .’ ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 Transparency ... announced the addition of a comprehensive report on ... ‘Infusion System Market (Large Volume, Disposable, Syringe, Ambulatory ... Growth, Trends And Forecast, 2013 – 2019’ is ... http://www.transparencymarketresearch.com . , To begin with, the ...
(Date:8/1/2014)... CentraComm, a leading managed IT security ... the Pure Storage® Authorized Reseller program. , ... experience designed to meet the rigorous resiliency, scalability, ... diverse markets, and for a variety of high ... years. , The Pure Storage FlashArray was ...
Breaking Medicine News(10 mins):Health News:Carbs May Contribute to Colon Cancer 2Health News:MonaVie Records 500th Commission Week, Having Paid Out More Than $1.4B in Distributor Commissions 2Health News:Discount-Dress.com’s Top Trend Report: 2014 Summer Short Bridesmaid Dresses Now for Sale 2Health News:Transparency Market Research Adds Report on Global Infusion System Market to its Repository 2Health News:Transparency Market Research Adds Report on Global Infusion System Market to its Repository 3Health News:CentraComm Accepts Pure Storage Authorized Reseller Partner Invitation 2Health News:CentraComm Accepts Pure Storage Authorized Reseller Partner Invitation 3
... Royer Animal Health, LLC, a wholly owned subsidiary ... agreement with MWI Veterinary, Supply, Inc. (Nasdaq: ... MATRIX III CISPLATIN BEADS and R-GEL ... products provide veterinary professionals with localized treatment options for ...
... of many public services to head off infections , , ... swine flu cases in the United States has surpassed 100, ... to be the source of the outbreak -- braced for ... limit further infections in that country, where the virus is ...
... flu topping the agenda of,business around the world, global ... revealing the countries most at risk from an,influenza pandemic. ... Index (IPRI) consists of three categories:,Risk of Emergence, Risk ... list of countries most at risk and that require ...
... April 30 The Providence Service Corporation (Nasdaq: ... to report financial results for its first quarter ended March ... closes.Providence will hold a conference call at 11:00 a.m. EDT ... May 7, 2009, to discuss its financial results and corporate ...
... the world exercise in unison for 21st annual Project ACES ... the globe will walk, jog, bike or play games on ... (All Children Exercise Simultaneously) Day. This Youth Fitness ... College of Sports Medicine ,s Exercise is ...
... PREPARES FOR LAUNCH OF ,NEST-3, ACUTE ISCHEMIC STROKE CLINICAL ... of transcranial laser therapy (TLT) designed for the treatment ... onset, announced today that it has closed a $50 ... Pincus, a leading global private equity firm, to fund ...
Cached Medicine News:Health News:Royer Animal Health Enters Into Exclusive Agreement With MWI Veterinary Supply for U.S. Distribution of Next-Generation Therapeutics to Treat Cancer and Infections 2Health News:Swine Flu Infections Surpass 100 in U.S. 2Health News:Swine Flu Infections Surpass 100 in U.S. 3Health News:Swine Flu Infections Surpass 100 in U.S. 4Health News:Swine Flu Infections Surpass 100 in U.S. 5Health News:Swine Flu Infections Surpass 100 in U.S. 6Health News:Maplecroft Flu Pandemic Maps Reveal Countries Most at Risk 2Health News:Providence Service Corporation to Report First Quarter 2009 Results on Wednesday, May 6th After the Market Closes 2Health News:Providence Service Corporation to Report First Quarter 2009 Results on Wednesday, May 6th After the Market Closes 3Health News:Youth to Fight Obesity With World's Largest Exercise Class 2Health News:Youth to Fight Obesity With World's Largest Exercise Class 3Health News:PhotoThera Closes $50 Million Financing, Announces New President and Chief Executive Officer 2Health News:PhotoThera Closes $50 Million Financing, Announces New President and Chief Executive Officer 3
The Active Ankle Trainer model provides medial/lateral support and optimum ankle mobility for chronic and prophylactic use....
... The Bledsoe PTB Boot is ... alternative to casting for the mid-tibia ... providing patella tendon bearing support. The ... designed for range of motion from ...
... The Bledsoe Hi-Top Boot is designed ... casting for the mid-tibia or fibula to ... third degree ankle sprains. The Bledsoe EZ ... of motion from 20 degrees of dorsi-flexion ...
... Cronin, Inc. is a ... Footwear, Orthopedic Softgoods, and ... Our products are of ... available in the USA ...
Medicine Products: